|Bid||2.7200 x 800|
|Ask||3.2500 x 800|
|Day's Range||2.6800 - 2.7900|
|52 Week Range||2.3200 - 4.4600|
|Beta (3Y Monthly)||1.18|
|PE Ratio (TTM)||54.60|
|Earnings Date||Dec 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
Enzo Biochem, Inc. (NYSE:ENZ), an integrated diagnostics and life sciences company focusing on delivering and applying advanced technology capabilities to produce affordable, reliable products and services that enable its customers to meet their clinical needs, today issued an open letter to shareholders. Full text below:
Enzo Biochem, Inc. (NYSE:ENZ) will hold a conference call to discuss fiscal 2020 first quarter results on Tuesday, December 10, 2019, at 4:30 PM E.T.
Company’s Vertically Integrated Life Sciences and Labs Business Generates Breakthrough Diagnostic Testing Approvals and Services in Rapidly Expanding Markets
Enzo Biochem, Inc. (ENZ) will hold a conference call to discuss fiscal 2019 fourth quarter and fiscal year 2019 results on Tuesday, October 15, 2019, at 4:30 PM E.T. To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024.
For many, the main point of investing is to generate higher returns than the overall market. But even the best stock...
If you're interested in Enzo Biochem, Inc. (NYSE:ENZ), then you might want to consider its beta (a measure of share...
NEW YORK, NY / ACCESSWIRE / June 11, 2019 / Enzo Biochem, Inc. (NYSE: ENZ ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on June 11, 2019 at 8:30 AM Eastern ...
To listen to the conference call dial 1-888-459-5609. International callers can dial 1-973-321-1024. A rebroadcast of the call will be available starting approximately two hours after the conference call ends, through 12 AM (E.T.) Tuesday June 25, 2019.
Enzo Biochem, Inc. (ENZ) today announced that on May 7, 2019 it was issued U.S. Patent No. 10,278,960 entitled “Sphingosine Pathway Modulating Compounds for the Treatment of Cancers” that is directed to methods for treating hepatocellular carcinoma (HCC), the most common human liver cancer, using the compound Ozanimod. Ozanimod is a product of Celgene Corporation (CELG) that is in late-stage clinical development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease. It targets a different part of the same cell signaling pathway, the “sphingosine pathway,” also targeted by Enzo’s proprietary sphingosine kinase inhibitor, SK1-I, which Enzo is currently developing for the treatment of HCC.
After nearly 38 years, small cap, biotech expert Bill Mathews is retiring as editor of The Cheap Investor; we wish Bill and his wife Karen the very best for their coming years. Meanwhile, we leave our readers with some of Bill's parting comments on some of his favorite biotech ideas.
A look at the shareholders of Enzo Biochem, Inc. (NYSE:ENZ) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the small...
On a per-share basis, the New York-based company said it had a loss of 18 cents. The life sciences and biotechnology company posted revenue of $19.3 million in the period. In the final minutes of trading ...
Enzo Biochem, Inc. , an integrated diagnostics and therapeutics company, today reported results for the fiscal quarter and first half ended January 31, 2019 along with providing more detail on its investments in the development of novel diagnostic system and centralized clinical services.